Ascendis Pharma A/S (NASDAQ:ASND) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the fourteen brokerages that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and thirteen have given a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $192.07.

Several research analysts have recently issued reports on the company. UBS Group began coverage on Ascendis Pharma A/S in a research report on Tuesday. They issued a "buy" rating and a $196.00 price target on the stock. Evercore ISI boosted their target price on Ascendis Pharma A/S from $191.00 to $205.00 and gave the stock an "outperform" rating in a research report on Tuesday, September 17th. StockNews.com raised shares of Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a research note on Wednesday, November 20th. Wedbush reiterated an "outperform" rating and issued a $181.00 target price on shares of Ascendis Pharma A/S in a report on Friday, November 15th. Finally, TD Cowen decreased their price target on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a "buy" rating for the company in a report on Friday, November 15th.

Institutional Trading of Ascendis Pharma A/S

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Wilmington Savings Fund Society FSB bought a new position in shares of Ascendis Pharma A/S in the 3rd quarter valued at about $30,000. Groupama Asset Managment bought a new position in Ascendis Pharma A/S during the third quarter worth about $60,000. GAMMA Investing LLC increased its position in Ascendis Pharma A/S by 58.0% during the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock worth $80,000 after buying an additional 214 shares during the last quarter. Signaturefd LLC raised its stake in Ascendis Pharma A/S by 13.2% in the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company's stock valued at $102,000 after buying an additional 80 shares during the period. Finally, Rhumbline Advisers lifted its position in shares of Ascendis Pharma A/S by 10.3% in the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company's stock valued at $209,000 after buying an additional 143 shares during the last quarter.

Ascendis Pharma A/S Stock Performance

ASND traded down $2.86 during mid-day trading on Thursday, reaching $134.43. The stock had a trading volume of 500,335 shares, compared to its average volume of 400,966. The firm's fifty day simple moving average is $132.53 and its two-hundred day simple moving average is $133.60. The stock has a market capitalization of $8.16 billion, a P/E ratio of -16.64 and a beta of 0.65. Ascendis Pharma A/S has a 52 week low of $111.09 and a 52 week high of $161.00.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.